156 related articles for article (PubMed ID: 16545010)
1. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.
Hornberger J; Kilby JM; Wintfeld N; Green J
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):240-7. PubMed ID: 16545010
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy.
Hornberger J; Green J; Wintfeld N; Cavassini M; Rockstroh J; Giuliani G; De Carli C; Lazzarin A
HIV Clin Trials; 2005; 6(2):92-102. PubMed ID: 15983893
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.
Sax PE; Losina E; Weinstein MC; Paltiel AD; Goldie SJ; Muccio TM; Kimmel AD; Zhang H; Freedberg KA; Walensky RP
J Acquir Immune Defic Syndr; 2005 May; 39(1):69-77. PubMed ID: 15851916
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of enfuvirtide (ENF) added to an optimized therapy compared with an optimized therapy in patients with HIV/AIDS.
Badia X; Lizán L; Magaz S; Sanz AC; Green J; Serrano D
HIV Clin Trials; 2007; 8(4):235-45. PubMed ID: 17720664
[TBL] [Abstract][Full Text] [Related]
5. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
Reynes J; Arastéh K; Clotet B; Cohen C; Cooper DA; Delfraissy JF; Eron JJ; Henry K; Katlama C; Kuritzkes DR; Lalezari JP; Lange J; Lazzarin A; Montaner JS; Nelson M; O' Hearn M; Stellbrink HJ; Trottier B; Walmsley SL; Buss NE; Demasi R; Chung J; Donatacci L; Guimaraes D; Rowell L; Valentine A; Wilkinson M; Salgo MP
AIDS Patient Care STDS; 2007 Aug; 21(8):533-43. PubMed ID: 17711378
[TBL] [Abstract][Full Text] [Related]
6. The lifetime cost of current human immunodeficiency virus care in the United States.
Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
[TBL] [Abstract][Full Text] [Related]
7. Adherence to enfuvirtide and its impact on treatment efficacy.
Rockstroh J; Dejesus E; Donatacci L; Wat C; Bertasso A; Labriola-Tompkins E; Shikhman A; Atkins B; Guimaraes D; Wilkinson M; Thommes J; Rowell L; Demasi R; Salgo M
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):141-8. PubMed ID: 18240965
[TBL] [Abstract][Full Text] [Related]
8. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
Ruof J; Dusek A; DeSpirito M; Demasi RA
Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.
Charpentier C; Jenabian MA; Piketty C; Karmochkine M; Tisserand P; Laureillard D; Bélec L; Si-Mohamed A; Weiss L
Scand J Infect Dis; 2011 May; 43(5):373-9. PubMed ID: 21341978
[TBL] [Abstract][Full Text] [Related]
10. Enfuvirtide (Fuzeon): the first fusion inhibitor.
Williams IG
Int J Clin Pract; 2003 Dec; 57(10):890-7. PubMed ID: 14712892
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials for enfuvirtide (Fuzeon, T-20).
Crabb C
AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
[No Abstract] [Full Text] [Related]
12. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.
Raffi F; Katlama C; Saag M; Wilkinson M; Chung J; Smiley L; Salgo M
Clin Infect Dis; 2006 Mar; 42(6):870-7. PubMed ID: 16477567
[TBL] [Abstract][Full Text] [Related]
13. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study.
Bonora S; Calcagno A; Cometto C; Fontana S; Aguilar D; D'Avolio A; Gonzalez de Requena D; Maiello A; Dal Conte I; Lucchini A; Di Perri G
Infection; 2012 Feb; 40(1):69-75. PubMed ID: 22135137
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen.
Cohen CJ; Clumeck N; Molina JM; Thompson M; Patel K; Wintfeld N; Green J
J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1140-6. PubMed ID: 15319673
[TBL] [Abstract][Full Text] [Related]
15. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
Youle M; Staszweski S; Clotet B; Arribas JR; Blaxhult A; Carosi G; Dejesus E; Di Perri G; Estrada V; Fisher M; Kovacs C; Kulasegaram R; Lazzarin A; Marriott D; Muñoz L; Reynes J; Shalit P; Slim J; Tsoukas C; Vaccaro A; Vera J
HIV Clin Trials; 2006; 7(2):86-96. PubMed ID: 16798623
[TBL] [Abstract][Full Text] [Related]
16. Patients' perception and effectiveness of a treatment containing enfuvirtide when used in HIV-infected patients without very advanced disease.
Pulido F; Del Pozo MA; Fernández-Guerrero M; Moreno A; Oteo JA; Flores J; Pedrol E; Torres R; Padilla B; Téllez MJ; García J; González-García J;
HIV Clin Trials; 2008; 9(2):83-90. PubMed ID: 18474493
[TBL] [Abstract][Full Text] [Related]
17. Immunological and virological study of enfuvirtide-treated HIV-positive patients.
Barretina J; Blanco J; Bonjoch A; Llano A; Clotet B; Esté JA
AIDS; 2004 Aug; 18(12):1673-82. PubMed ID: 15280778
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico.
Contreras-Hernandez I; Becker D; Chancellor J; Kühne F; Mould-Quevedo J; Vega G; Marfatia S
Value Health; 2010 Dec; 13(8):903-14. PubMed ID: 21091827
[TBL] [Abstract][Full Text] [Related]
19. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.
Poveda E; Rodés B; Labernardière JL; Benito JM; Toro C; González-Lahoz J; Faudon JL; Clavel F; Schapiro J; Soriano V
J Med Virol; 2004 Sep; 74(1):21-8. PubMed ID: 15258964
[TBL] [Abstract][Full Text] [Related]
20. Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure.
Cossarini F; Galli L; Sagnelli C; Gianotti N; Hasson H; Clementi M; Soria A; Salpietro S; Lazzarin A; Castagna A
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):179-84. PubMed ID: 19352200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
